Idera Pharmaceuticals, Inc. Company Profile
Idera Pharmaceuticals develops drug candidates to treat infectious
diseases, autoimmune and inflammatory diseases, cancer, and respiratory
diseases, and for use as vaccine adjuvants. Our proprietary drug
candidates are designed to modulate specific Toll-like Receptors, which
are a family of immune system receptors that direct immune system
responses. Our pioneering DNA and RNA chemistry expertise enables us to
create drug candidates for internal development and generates
opportunities for multiple collaborative alliances. For more
information, visit www.iderapharma.com.
News Articles
Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial
Idera Pharmaceuticals (NASDAQ:IDRA) is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like recepto...
5 Top Weekly NASDAQ Biotech Stocks: Idera Rises to the Top
Idera Pharmaceuticals, Eiger Biopharma, Aevi Genomic Medicine, Evofem Biosciences and Biospecifics Tech were last week's top gainers on the NASDAQ Biotechnology Index. The post 5 Top Weekly NASDAQ Bi...
Idera Pharmaceuticals Announces Corporate Organizational Changes
- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors - - Chief Financial Officer Louis J. Arcudi III departing the company related to company consolidation to Pennsy...
Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
EXTON, Pa., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednes...
Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference
EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulat...
Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors
EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modula...
Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors
EXTON, Pa., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18, 2018. Ms. Sc...
Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Abstract accepted for 2018 European Society of Medical Oncology Annual Meeting Cash runway into first quarter of 2020 EXTON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (N...
Drugs and Medications
None
PubMed Articles
Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.
Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...
Insight into the distribution of pharmaceuticals in soil-water-plant systems.
Pharmaceuticals in agricultural soils originating from irrigation with treated wastewater and land-applied biosolids can enter field crops. However, little is known about the role of pore water in pla...
Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...
The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...
Surface water concentrations of 54 pharmaceuticals were predicted for seven major Swedish rivers and the Stockholm City area basins using the STREAM-EU model. These surface water concentrations were u...
Clinical Trials
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet
Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...
Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet
Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...
- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...
Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...
Cilostazol 50 mg Tablets Under Fasting Conditions
This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...
Companies
Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvan...
We are a biotechnology company engaged in the discovery and development of novel therapeutics that modulate immune responses through Toll-like receptors (TLR) for the treatment of multiple diseases.Id...
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvan...
Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...
More Information about "Idera Pharmaceuticals, Inc." on BioPortfolio
We have published hundreds of Idera Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Idera Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Idera Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Idera Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Idera Pharmaceuticals, Inc. Drugs and Medications on this site too.
